Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Other Non-Current Liabilities (2020 - 2026)

Opus Genetics has reported Other Non-Current Liabilities over the past 10 years, most recently at $77.3 million for Q1 2026.

  • Quarterly Other Non-Current Liabilities changed N/A to $77.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $77.3 million through Mar 2026, changed N/A year-over-year, with the annual reading at $26.0 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities was $77.3 million for Q1 2026 at Opus Genetics, up from $26.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $77.3 million in Q1 2026 and troughed at $74000.0 in Q4 2023.
  • The 4-year median for Other Non-Current Liabilities is $1.2 million (2023), against an average of $16.7 million.